EdgeRx vs Peak Wellness
Two GLP-1 desks, one scoreboard. We put EdgeRx and Peak Wellness head-to-head on the published Brief Score — the same six factors, scored the same way.
EdgeRx
The verdict
EdgeRx takes this head-to-head.
EdgeRx scores 84 to 83 on our six-factor Brief Score — A men's-only protocol shop with flat, disclosed GLP-1 pricing, a named Chief Medical Advisor, and a named 503A compounding pharmacy — rare transparency for this tier of the ranking.
That doesn't make Peak Wellness a bad call — it's best for readers drawn to a consumer-brand experience who are comfortable vetting an unaccredited desk themselves. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| EdgeRx | Peak Wellness | |
|---|---|---|
| Brief Score | 84/100 (B) | 83/100 (B) |
| Semaglutide | $229/mo injectable | $249/mo |
| Tirzepatide | $299/mo injectable | $349/mo |
| Coverage | 46 states (excludes Arkansas, Indiana, Minnesota, South Carolina) | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Newnew to the tracker, no prior reading | Stableprice stable |
EdgeRx: First reading — flat weekly-injectable pricing on both molecules, named CMA and named 503A pharmacy.
Peak Wellness: $249 sema / $349 tirz nationwide; no accreditation listed.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.